XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.7255
+0.0029 (0.40%)
At close: Aug 1, 2025, 4:00 PM
0.7390
+0.0135 (1.86%)
After-hours: Aug 1, 2025, 5:58 PM EDT

Company Description

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease.

Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy.

It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance.

The company is based in Calgary, Canada.

XORTX Therapeutics Inc.
XORTX Therapeutics logo
CountryCanada
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees3
CEOAllen Davidoff

Contact Details

Address:
3710 – 33rd Street NW
Calgary, AB T2L 2M1
Canada
Phone403-455-7727
Websitexortx.com

Stock Details

Ticker SymbolXRTX
ExchangeNASDAQ
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001729214
CUSIP Number98420Q207
ISIN NumberCA98420Q3061
SIC Code2834

Key Executives

NamePosition
Dr. Allen Warren Davidoff Ph.D.Founder, Chief Executive Officer, President and Director
Dr. Michael Scott Bumby D.V.M., M.B.A.Chief Financial Officer
Dr. Stephen Haworth M.D., MRCPChief Medical Officer
Dr. Stacy Evans M.B.A., M.D.Chief Business Officer
Nick RigopoulosDirector of Communications
Dr. David Sans M.B.A., Ph.D.Director of Corporate Development
Dr. David MacDonald Ph.D.Consultant of Clinical Operations
Charlotte MayCorporate Secretary

Latest SEC Filings

DateTypeTitle
Jun 26, 20256-KReport of foreign issuer
May 19, 20256-KReport of foreign issuer
May 16, 20256-KReport of foreign issuer
May 15, 2025SCHEDULE 13G/AFiling
May 12, 202520-FAnnual and transition report of foreign private issuers
May 1, 2025NT 20-FNotification of inability to timely file Form 20-F
Apr 30, 20256-KReport of foreign issuer
Apr 28, 20256-KReport of foreign issuer
Apr 18, 20256-KReport of foreign issuer
Apr 1, 20256-KReport of foreign issuer